<DOC>
	<DOCNO>NCT02551809</DOCNO>
	<brief_summary>The purpose Phase IIa study determine whether AD Immunotherapeutic Vaccine ( UB-311 ) , target amyloid beta peptide ( N-terminal amino acid , 1-14 ) , safe immunogenic mild AD patient . In addition , efficacy profile evaluate secondary endpoint .</brief_summary>
	<brief_title>Evaluate Safety , Tolerability , Immunogenicity Efficacy UB-311 Mild Alzheimer 's Disease ( AD ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Diagnosis mild Alzheimer 's Disease MiniMental State Examination ( MMSE ) score 20 26 ( inclusive ) Clinical dementia rating ( CDR ) score 0.5 1 Other inclusion criterion apply Clinically significant neurological disease Alzheimer 's disease Major psychiatric disorder Severe systemic disease Serious adverse reaction vaccine Other exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>